High-dose biotin for multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials

2021 ◽  
pp. 103159
Author(s):  
Adrian I. Espiritu ◽  
Patricia Pauline M. Remalante-Rayco
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
High Dose ◽  
Randomized Controlled

Efficacy of probiotics in multiple sclerosis: a systematic review of preclinical trials and meta-analysis of randomized controlled trials

2021 ◽  
Author(s):  
Jinchi Jiang ◽  
Chuanqi Chu ◽  
Caie Wu ◽  
Chen Wang ◽  
Chengcheng Zhang ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Randomized Controlled Trials ◽  
Potential Role ◽  
Meta Analysis ◽  
Preliminary Evidence ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Preclinical Trials

Preliminary evidence shows the potential role of probiotics in ameliorating multiple sclerosis (MS); however, the effects of probiotics on MS remain unclear.

scholarly journals Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials

2021 ◽  
Vol 12 ◽  
Author(s):  
Zhao Zhao ◽  
Chun-Lai Ma ◽  
Zhi-Chun Gu ◽  
Yue Dong ◽  
Yang Lv ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Virus Infection ◽  
Randomized Controlled Trials ◽  
Respiratory Infection ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Lower Respiratory Infection ◽  
Risk Of Infection ◽  
Randomized Controlled

Background and Aims: There is a controversy regarding whether fingolimod is associated with an increased risk of infection in patients with multiple sclerosis (MS). We performed a systematic review and meta-analysis of data from randomized controlled trials (RCTs) to determine the risk of infection in these patients.Methods: We systematically searched PubMed, EMBASE, the Cochrane Library, and clinicaltrials.gov from inception to April 8, 2020, to identify RCTs that reported the occurrence of infection in patients with MS treated with fingolimod. Relative risks (RRs) and 95% confidence intervals (95% CIs) were calculated using the random-effects model.Results: Twelve RCTs including 8,448 patients were eligible. Compared with the control (placebo and other active treatments), fingolimod significantly increased the risk of infection (RR, 1.16; 95% CI, 1.07–1.27; I2, 81%), regardless of whether the infection was a general infection (RR, 1.14; 95% CI, 1.05–1.25; I2, 78%), or a serious infection (RR, 1.49; 95% CI, 1.06–2.10; I2, 0%). Analyses of subgroups found that fingolimod significantly increased the risk of lower respiratory infection (RR, 1.48; 95% CI, 1.19–1.85; I2, 0%) and herpes virus infection (RR, 1.34; 95% CI, 1.01–1.78; I2, 9%). There appears to be no dose-dependent increase in the risk of infection associated with fingolimod (0.5 mg: RR, 1.15; 95% CI, 1.07–1.25; I2, 91%; 1.25 mg: RR, 1.11; 95% CI, 0.97–1.28; I2, 81%; Pinteraction = 0.66).Conclusions: Compared with a placebo and other active treatments, fingolimod was associated with a 16% increase in the risk of infection, especially lower respiratory infection and herpes virus infection. The risk of infection associated with fingolimod might not be dose related.

Sign in / Sign up

Export Citation Format

Share Document